SCHEMBL9450890

SCHEMBL9450890

C1CN(N2CC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229984 0.94
SCHEMBL5909605 0.94
SCHEMBL2778576 0.89
SCHEMBL513824 0.89
SCHEMBL2126834 0.89
SCHEMBL13835190 0.84
SCHEMBL19878898 0.84
SCHEMBL13836035 0.84 MGLL (0.38)
SCHEMBL1428237 0.84 MGLL (0.38)
SCHEMBL3273654 0.84 MGLL (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232114-A SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2022-10-25 CN claimed
CN-115232111-A SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2022-10-25 CN claimed
WO-2024047674-A1 MANGANESE BASED CATALYST, ITS PROCESS OF PREPARATION AND THEIR USE IN PROCESS OF HYDROGENATION REACTIONS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-03-07 WO disclosed
WO-2024042544-A1 NICKEL-BASED CATALYSTS FOR THE SELECTIVE (DE)HYDROGENATIVE COUPLING OF BENZYL ALCOHOLS WITH AZOBENZENES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2024-02-29 WO disclosed
US-20230286928-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2023-09-14 US disclosed
EP-3807254-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE Epigen Biosciences, Inc. (US) 2021-04-21 EP disclosed
EP-2988743-B1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES INC (US) 2020-12-09 EP disclosed
EP-3710431-A1 SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME Aclaris Therapeutics, Inc. (US) 2020-09-23 EP disclosed
US-20200181099-A1 Heterocyclic Compounds Useful In The Treatment Of Disease EPIGEN BIOSCIENCES, INC. (US) 2020-06-11 US disclosed
US-10570103-B2 Heterocyclic compounds useful in the treatment of disease EPIGEN BIOSCIENCES, INC. (US) 2020-02-25 US disclosed
US-20190135767-A1 Heterocyclic Compounds Useful In The Treatment Of Disease EPIGEN BIOSCIENCES, INC. (US) 2019-05-09 US disclosed
EP-3116486-A2 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE Capon, Daniel J. (US) 2017-01-18 EP disclosed
EP-2988743-A2 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE Epigen Biosciences, Inc. (US) 2016-03-02 EP disclosed
US-20160024031-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2016-01-28 US disclosed
EP-2958558-A2 METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA Golden Biotechnology Corporation (US) 2015-12-30 EP disclosed
WO-2015138907-A2 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE CAPON DANIEL J (US) 2015-09-17 WO disclosed
US-20150259592-A1 Coated And Cured Proppants PREFERRED TECHNOLOGY, LLC 2015-09-17 US disclosed
WO-2014145873-A2 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2014-09-18 WO disclosed
WO-2014130619-A2 METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA GOLDEN BIOTECHNOLOGY CORPORATION (US) 2014-08-28 WO disclosed
EP-0537338-A1 THERMALLY STABLE COMPOSITIONS AND LUBRICANTS AND FUNCTIONAL FLUIDS CONTAINING THE SAME. LUBRIZOL CORP (US) 1993-04-21 EP disclosed